These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 26657044)

  • 21. A novel approach using telomerase-specific replication-selective adenovirus for detection of circulating tumor cells in breast cancer patients.
    Kim SJ; Masago A; Tamaki Y; Akazawa K; Tsukamoto F; Sato J; Ozawa T; Tsujino Y; Noguchi S
    Breast Cancer Res Treat; 2011 Aug; 128(3):765-73. PubMed ID: 21630023
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of Circulating Tumor Cells in Breast Cancer Patients Using Cytokeratin-19 Real-Time RT-PCR.
    Park HS; Han HJ; Lee S; Kim GM; Park S; Choi YA; Lee JD; Kim GM; Sohn J; Kim SI
    Yonsei Med J; 2017 Jan; 58(1):19-26. PubMed ID: 27873491
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer.
    Mu Z; Wang C; Ye Z; Austin L; Civan J; Hyslop T; Palazzo JP; Jaslow R; Li B; Myers RE; Jiang J; Xing J; Yang H; Cristofanilli M
    Breast Cancer Res Treat; 2015 Dec; 154(3):563-71. PubMed ID: 26573830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients.
    Aktas B; Kasimir-Bauer S; Müller V; Janni W; Fehm T; Wallwiener D; Pantel K; Tewes M;
    BMC Cancer; 2016 Jul; 16():522. PubMed ID: 27456970
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circulating levels of transforming growth factor-βeta (TGF-β) and chemokine (C-X-C motif) ligand-1 (CXCL1) as predictors of distant seeding of circulating tumor cells in patients with metastatic breast cancer.
    Divella R; Daniele A; Savino E; Palma F; Bellizzi A; Giotta F; Simone G; Lioce M; Quaranta M; Paradiso A; Mazzocca A
    Anticancer Res; 2013 Apr; 33(4):1491-7. PubMed ID: 23564790
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden.
    Cristofanilli M; Broglio KR; Guarneri V; Jackson S; Fritsche HA; Islam R; Dawood S; Reuben JM; Kau SW; Lara JM; Krishnamurthy S; Ueno NT; Hortobagyi GN; Valero V
    Clin Breast Cancer; 2007 Feb; 7(6):471-9. PubMed ID: 17386124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients.
    Königsberg R; Obermayr E; Bises G; Pfeiler G; Gneist M; Wrba F; de Santis M; Zeillinger R; Hudec M; Dittrich C
    Acta Oncol; 2011 Jun; 50(5):700-10. PubMed ID: 21261508
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation of hormone receptor status between circulating tumor cells, primary tumor, and metastasis in breast cancer patients.
    Kalinsky K; Mayer JA; Xu X; Pham T; Wong KL; Villarin E; Pircher TJ; Brown M; Maurer MA; Bischoff FZ
    Clin Transl Oncol; 2015 Jul; 17(7):539-46. PubMed ID: 25613123
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circulating tumor cells in breast cancer--current status and perspectives.
    Banys-Paluchowski M; Krawczyk N; Meier-Stiegen F; Fehm T
    Crit Rev Oncol Hematol; 2016 Jan; 97():22-9. PubMed ID: 26563820
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes in keratin expression during metastatic progression of breast cancer: impact on the detection of circulating tumor cells.
    Joosse SA; Hannemann J; Spötter J; Bauche A; Andreas A; Müller V; Pantel K
    Clin Cancer Res; 2012 Feb; 18(4):993-1003. PubMed ID: 22228641
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Classification of circulating tumor cells by epithelial-mesenchymal transition markers.
    Wu S; Liu S; Liu Z; Huang J; Pu X; Li J; Yang D; Deng H; Yang N; Xu J
    PLoS One; 2015; 10(4):e0123976. PubMed ID: 25909322
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel monoclonal antibody L2A5 specifically targeting sialyl-Tn and short glycans terminated by alpha-2-6 sialic acids.
    Loureiro LR; Sousa DP; Ferreira D; Chai W; Lima L; Pereira C; Lopes CB; Correia VG; Silva LM; Li C; Santos LL; Ferreira JA; Barbas A; Palma AS; Novo C; Videira PA
    Sci Rep; 2018 Aug; 8(1):12196. PubMed ID: 30111774
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-recovery visual identification and single-cell retrieval of circulating tumor cells for genomic analysis using a dual-technology platform integrated with automated immunofluorescence staining.
    Campton DE; Ramirez AB; Nordberg JJ; Drovetto N; Clein AC; Varshavskaya P; Friemel BH; Quarre S; Breman A; Dorschner M; Blau S; Blau CA; Sabath DE; Stilwell JL; Kaldjian EP
    BMC Cancer; 2015 May; 15():360. PubMed ID: 25944336
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytometric characterization of circulating tumor cells captured by microfiltration and their correlation to the CellSearch(®) CTC test.
    Adams DL; Stefansson S; Haudenschild C; Martin SS; Charpentier M; Chumsri S; Cristofanilli M; Tang CM; Alpaugh RK
    Cytometry A; 2015 Feb; 87(2):137-44. PubMed ID: 25515318
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Prognostic Value of HER2-Positive Circulating Tumor Cells in Breast Cancer Patients: A Systematic Review and Meta-Analysis.
    Wang CH; Chang CJ; Yeh KY; Chang PH; Huang JS
    Clin Breast Cancer; 2017 Aug; 17(5):341-349. PubMed ID: 28347604
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Advanced detection and measurement of cells on membrane from peripheral blood by laser scanning cytometry (LSC) in early stage breast cancer patients.
    Sanislo L; Kuliffay P; Sedlak J; Kausitz J; Galbavy S
    Bratisl Lek Listy; 2010; 111(1):13-9. PubMed ID: 20429306
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial.
    Jaeger BAS; Neugebauer J; Andergassen U; Melcher C; Schochter F; Mouarrawy D; Ziemendorff G; Clemens M; V Abel E; Heinrich G; Schueller K; Schneeweiss A; Fasching P; Beckmann MW; Scholz C; Friedl TWP; Friese K; Pantel K; Fehm T; Janni W; Rack B
    PLoS One; 2017; 12(6):e0173593. PubMed ID: 28586395
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.
    Iwata H; Masuda N; Yamamoto D; Sagara Y; Sato N; Yamamoto Y; Saito M; Fujita T; Oura S; Watanabe J; Tsukabe M; Horiguchi K; Hattori S; Matsuura Y; Kuroi K
    Breast Cancer Res Treat; 2017 Apr; 162(3):501-510. PubMed ID: 28181129
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer.
    Mu Z; Wang C; Ye Z; Rossi G; Sun C; Li L; Zhu Z; Yang H; Cristofanilli M
    Breast Cancer Res Treat; 2017 Oct; 165(3):733-741. PubMed ID: 28687903
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Potential of Circulating Tumor Cells in Personalized Management of Breast Cancer: A Systematic Review.
    Khatami F; Aghayan HR; Sanaei M; Heshmat R; Tavangar SM; Larijani B
    Acta Med Iran; 2017 Mar; 55(3):175-193. PubMed ID: 28282718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.